

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

Fred Hutchinson Cancer Center Immune Monitoring Core Facility

RRID:SCR_022615

Type: Tool

Proper Citation

Fred Hutchinson Cancer Center Immune Monitoring Core Facility (RRID:SCR_022615)

Resource Information

URL: <https://www.fredhutch.org/en/research/shared-resources/core-facilities/immune-monitoring.html>

Proper Citation: Fred Hutchinson Cancer Center Immune Monitoring Core Facility (RRID:SCR_022615)

Description: Supports investigators seeking evaluations of immunologic responses in basic and early stage clinical research settings. Provides resources and expertise to evaluate cellular immunologic processes and responses through reagents, molecular and cellular assays, assay development support and research consulting services.

Synonyms: Fred Hutchinson Cancer Center Immune Monitoring Shared Resource

Resource Type: access service resource, core facility, service resource

Keywords: immunologic responses, evaluate cellular immunologic processes, molecular and cellular assays, assay development support, research consulting services, ABRF, USEDit, NACCSR

Availability: Open

Resource Name: Fred Hutchinson Cancer Center Immune Monitoring Core Facility

Resource ID: SCR_022615

Alternate IDs: ABRF_1531

Alternate URLs: https://coremarketplace.org/RRID:SCR_022615/?citation=1

Record Creation Time: 20220802T050144+0000

Record Last Update: 20260919T195948+0000

Ratings and Alerts

No rating or validation information has been found for Fred Hutchinson Cancer Center Immune Monitoring Core Facility.

No alerts have been found for Fred Hutchinson Cancer Center Immune Monitoring Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Ozog S, et al. (2026) Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. Nature communications, 17(1).

Kuhlmann AS, et al. (2026) Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody. Antibodies (Basel, Switzerland), 15(1).

Zhang S, et al. (2026) A CD8?? co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands. Nature communications, 17(1), 753.

Chhan CB, et al. (2026) Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. Cell reports. Medicine, 7(2), 102618.